Thank you very much for your question.
I'll speak from the perspective of Moderna. We are about 13 years old today, which is preteen years, and we've been investing in research and development for 13 years. The investment we made in our mRNA platform enabled us to be able to respond very quickly during the pandemic and bring a vaccine to Canadians on December 24, 2020. Our vaccine was able to reach places like Scarborough but also Yukon, the Northwest Territories and other more remote areas to protect indigenous communities and other more remote communities.
This is the fruit of significant investment in research and development. This is the result of significant investment in innovation. We must protect that innovation so that we can actually continue protecting the lives of patients, like those in Canada. That's where protecting intellectual property is absolutely critical, so that we can continue investing in research and development—not just us investing but all other members and companies in the life sciences ecosystem—and create a really strong innovation and life sciences ecosystem.
This is really important. It's important in the academic setting and it's important in the pharma industry. IP, or intellectual property, is really the key piece that we create so that we can have significant benefits for patients and save the lives of people, as we did here in Canada during the pandemic.